Valuation: Tengion, Inc.

Market Cap 1L 96.2T 88.92T 81.78T 2L 1.06Cr 2L 10.63L 4L 51.78L 4L 4L 1.78Cr P/E 2012
-0.14x
P/E 2013 -0.05x
Enterprise Value 55.52L 48.66L 44.98L 41.37L 78.05L 54Cr 79.31L 5.38Cr 2.11Cr 26Cr 2.08Cr 2.04Cr 90Cr EV / Sales 2012
-
EV / Sales 2013 -
Free-Float
100%
Yield 2012 *
-
Yield 2013 -
Change 5-day change 1-year change 3-year change Capi.($)
+0.70%+5.76%-35.11%-42.62% 64Cr
+26.99%+67.53%+249.66% - 51Cr
-3.22%-10.61%-43.82%+12.23% 11Cr
-2.50%-7.46%+14.23%+66.46% 11Cr
Average +5.40%+16.17%+46.24%+12.02% 34.42Cr
Weighted average by Cap. +9.79%+27.16%+74.49%-21.75%

Financials

2012 2013
Net sales - -
Net income -1.69Cr -1.48Cr -1.37Cr -1.26Cr -2.38Cr -163.25Cr -2.42Cr -16Cr -6.43Cr -80Cr -6.36Cr -6.22Cr -275.19Cr -1.89Cr -1.66Cr -1.53Cr -1.41Cr -2.66Cr -182.51Cr -2.7Cr -18Cr -7.19Cr -89Cr -7.11Cr -6.95Cr -307.67Cr
Net Debt 37.33L 32.72L 30.24L 27.82L 52.48L 36Cr 53.33L 3.62Cr 1.42Cr 18Cr 1.4Cr 1.37Cr 61Cr 54.42L 47.7L 44.09L 40.55L 76.51L 52Cr 77.74L 5.27Cr 2.07Cr 26Cr 2.04Cr 2Cr 88Cr
Logo Tengion, Inc.
Tengion, Inc. is a regenerative medicine company focused on discovering, developing, manufacturing and commercializing a range of neo-organs, or products composed of living cells, with or without synthetic or natural materials, implanted or injected into the body to engraft into, regenerate, or replace a damaged tissue or organ.  The Company, by using its Organ Regeneration Platform, it creates neo-organs using patient’s own cells.  The Company, based on its clinical and preclinical experience is leveraging its Organ Regeneration Platform to develop Neo-Kidney Augment for patients with advanced chronic kidney disease and Neo-Urinary Conduit for bladder cancer patients who are in need of a urinary diversion. The Company’s product candidates are intended to delay or eliminate the need for chronic disease therapies, organ transplantation, and the administration of anti-rejection medications.
Employees
-